Sign inJoin waitlistJoin the waitlist

Monica Davini

Assistant Professor, Clinical Scholar Path · University of Arizona College of Medicine-Tucson

Credentials: · · ·

History

University of Arizona College of Medicine-Tucson
Present
University of Arizona College of Medicine-Tucson
Present

Hematology and Medical Oncology
2019–2022
Pediatrics
University of California-San Francisco
2016–2019
Internal Medicine
Children’s Hospital and Research Center Oakland
2013–2016
Saint George's University School of Medicine
2009–2013

Research

What is in a name: defining pediatric refractory ITP
Blood Advances · 2024 · 6 citations
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor…
Pediatric Blood & Cancer · 2023 · 5 citations
The Utility of Serum Alpha-fetoprotein for Monitoring for Relapse of Alpha-fetoprotein-Positive Hepatoblastoma
Case report · Journal of Pediatric Hematology/Oncology · 2024 · First of 3 authors · 1 citations

Allison Remiker
2 papers
Kirsty Hillier
2 papers
Rachael Grace
2 papers
Sherif Badawy
2 papers
SK
Shipra Kaicker
2 papers
Taizo Nakano
2 papers
Amanda Grimes
1 paper
Amanda Jacobson-Kelly
1 paper
Caroline Hastings
1 paper
Christina Amend
1 paper · 1 as a resident
Cindy Neunert
1 paper
Corinna Schultz
1 paper

Clinical trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029